SCHEDULE 13G/A: Farallon Capital Group Discloses 9.9% Passive Stake in Enanta Pharmaceuticals

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 9.9% in Enanta Pharmaceuticals Inc. as of December 31, 2024.

Summary

• Farallon Capital Partners, L.P. and its affiliated funds (Farallon Funds) collectively hold 2,108,262 shares of Enanta Pharmaceuticals Inc. Common Stock.
• This aggregate ownership represents 9.9% of the outstanding class of Enanta Pharmaceuticals Inc. shares.
• The filing is an Amendment No. 6 to a Schedule 13G, indicating a routine update to previously disclosed ownership.
• The beneficial ownership is shared among various Farallon entities, including Farallon Capital Partners, L.P. (1.9%), Farallon Capital Institutional Partners, L.P. (2.2%), Farallon Capital Institutional Partners II, L.P. (0.5%), Farallon Capital Institutional Partners III, L.P. (0.3%), Four Crossings Institutional Partners V, L.P. (0.4%), Farallon Capital Offshore Investors II, L.P. (3.9%), Farallon Capital (AM) Investors, L.P. (0.2%), and Farallon Capital F5 Master I, L.P. (0.7%).
• Farallon Partners, L.L.C., as the general partner of several funds, and its managing members/senior managing members, including Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Rajiv A. Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly, are deemed beneficial owners of the total 9.9% stake.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative financial performance data or strategic announcements.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a significant institutional investment in a pharmaceutical company, which is common for large asset managers like Farallon Capital. It does not provide specific insights into broader industry trends beyond the investment itself.

Management Changes

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, indicating a large investor's position in the company. The passive nature of the filing suggests no immediate intent to influence corporate control.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Institutional Investor, Enanta Pharmaceuticals, Farallon Capital, Common Stock, SEC Filing, Passive Investment, Pharmaceuticals